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Abstract
Background: The central paradox of schizophrenia genetics is that susceptibility genes are preserved in the human gene-
pool against a strong negative selection pressure. Substantial evidence of epidemiology suggests that nuclear susceptibility
genes, if present, should be sustained by mutation-selection balance without heterozygote advantage. Therefore, putative
nuclear susceptibility genes for schizophrenia should meet special conditions for the persistence of the disease as well as
the condition of bearing a positive association with the disease.
Methodology/Principal Findings: We deduced two criteria that every nuclear susceptibility gene for schizophrenia should
fulfill for the persistence of the disease under general assumptions of the multifactorial threshold model. The first criterion
demands an upper limit of the case-control difference of the allele frequencies, which is determined by the mutation rate at
the locus, and the prevalence and the selection coefficient of the disease. The second criterion demands an upper limit of
odds ratio for a given allele frequency in the unaffected population. When we examined the top 30 genes at SZGene and
the recently reported common variants on chromosome 6p with the criteria using the epidemiological data in a large-
sampled Finnish cohort study, it was suggested that most of these are unlikely to confer susceptibility to schizophrenia. The
criteria predict that the common disease/common variant hypothesis is unlikely to fit schizophrenia and that nuclear
susceptibility genes of moderate effects for schizophrenia, if present, are limited to ‘rare variants’, ‘very common variants’, or
variants with exceptionally high mutation rates.
Conclusions/Significance: If we assume the nuclear DNA model for schizophrenia, it should have many susceptibility genes
of exceptionally high mutation rates; alternatively, it should have many disease-associated resistance genes of standard
mutation rates on different chromosomes. On the other hand, the epidemiological data show that pathogenic genes, if
located in the mitochondrial DNA, could persist through sex-related mechanisms.
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Introduction
While the development of genomics technology, coupled with
sophisticated designs of linkage and association studies, is opening
up new opportunities of genetics research of complex diseases, it
may still be important to view the study of human disease from an
epidemiological perspective [1]. The aim of this paper is to view
the recent findings of molecular genetics of schizophrenia (SZ) and
to examine the peculiarity of the genetic basis of SZ from an
epidemiological standpoint.
SZ is a common deleterious psychosis with high heritability (80–
85%), which manifests typically in adolescence or early adulthood
[2]. SZ crosses all cultures at a relatively high prevalence (0.5–1%)
[2,3], and seems to be an ancient condition. The incidence of SZ,
at the macro-level, varies within narrow limits [3], and appears to
be stable across generations in several countries [4,5]. On the
other hand, it has been well documented that patients with SZ
have a remarkably reduced reproductive fitness (0.3–0.8 as
compared with the value in the normal population; the reduction
is more pronounced in male patients) [6–17]. Then how can a
pathogenic gene predisposing to SZ persist against a strong
negative selection pressure? This ‘persistence problem’ has puzzled
scientists for long years [18–20].
From an evolutionary viewpoint, four explanations are possible
[18,20]: (i) mutation-selection balance, (ii) heterozygote advantage
(balancing selection), (iii) negative frequency-dependent selection,
and (iv) ancestral neutrality.
‘Ancestral neutrality’ assumes that reproductive fitness of
affected individuals and/or their relatives was higher in ancient
environments and that selection coefficients of pathogenic alleles
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times might be much smaller than now, pathogenic but neutral
alleles could have been fixed by genetic drift. While this hypothesis
explains that SZ has not been extinct in the long human history,
ancestral neutrality itself provides no explanation for the
apparently stable incidence of the disease across generations
today; although ‘ancestral neutrality’ might be plausible, it needs
another mechanism to account for the persistence of the disease in
modern environments, where the effective population size has
been expanded and the influence of negative selection pressure
may be much stronger than ever before.
‘Negative frequency-dependent selection’ explains the persis-
tence only when the fitness of the affected individuals increases as
the prevalence in the general population decreases, which seems
not to be the case with SZ.
‘Heterozygote advantage’ assumes that the susceptibility alleles
increase the fitness of the unaffected gene carriers, thereby
sustaining the gene frequencies. This line of explanations include:
(i) physiological advantage (resistance to shock, infections, and
poor nutrition etc.) [21], (ii) creative intelligence [22] or a higher
trait creativity including ‘everyday creativity’ [23], and (iii) a
higher sexual activity and/or attractiveness [24]. Since the
unaffected siblings of the patients are expected to share pathogenic
genes, those hypotheses need two lines of confirmation: (a) that the
unaffected siblings of the patients have such advantages, and (b)
that such advantages really contribute to sufficiently increase their
reproductive fitness.
Some of those hypotheses seem to gain the confirmation (a). For
example, Kinney et al. [23], in a well designed and methodolog-
ically sophisticated study, showed that an advantage of everyday
creativity was linked to a subtle clinical picture (schizotypal signs)
in a non-psychotic sample of SZ offspring.
However, those hypotheses lack the confirmation (b) in the
nuclear DNA (ncDNA) model; those hypotheses, although
theoretically plausible and fascinating, have not been supported
by most epidemiological studies, which show a decreased
reproductive fitness of the unaffected siblings of the patients
[14,16,17,25–28]. Haukka et al. [17], in a large-sampled cohort
study, showed an increased reproductive fitness of unaffected female
siblings of patients with SZ. However, this statistically higher
fertility of the female siblings (1.033) was not large enough to
compensate for the gene loss due to the decreased reproductive
fitness of the patients (0.346) and their male siblings (0.950) in the
ncDNA model. More recently, Svensson et al. [29], in a large-
sampled three generation cohort study, did not find an increased
fertility among parents, siblings or offspring of patients with SZ
(except for a slightly and not significantly increased fertility ,1.02
in healthy female siblings).
Thus, if we assume the ncDNA model for SZ, the remaining
possibility is the mechanism of mutation-selection balance without
heterozygote advantage. (Keller and Miller [20] comprehensively
discussed this problem, leading to a similar conclusion. The
difference from our argument is that Keller and Miller overlooked
the possibility of ‘ancestral heterozygote advantage’ and discussed
against ancestral neutrality.) Therefore, loss of the risk alleles due
to the decreased reproductive fitness of the patients should be
balanced by de novo mutation in each risk locus. A nuclear gene for
SZ should meet this ‘persistence condition’ in addition to the
condition of bearing a significant association with SZ. This simple
and essential principle has been overlooked in SZ genetics.
Here we deduce two criteria that a nuclear susceptibility gene
for SZ should fulfill for the persistence of the disease under general
assumptions of multifactorial threshold model, and present their
implications for genetic association studies and genetic models for
SZ using the epidemiological data in a large-sampled Finish cohort
study.
Results
We deduced a series of criteria (‘persistence criteria’) that every
nuclear susceptibility gene for SZ should fulfill for the persistence
of the disease against a strong negative selection pressure. While
the association condition between a risk allele and the disease
demands the lower limit zero of the case-control difference of the
allele frequencies (d~ M jj A{ M jj U; M jj A =allele frequency in
the affected population, M jj U =allele frequency in the unaffected
population), the first criterion demands an upper limit v of the
difference, which is determined by the prevalence of the disease
(p), the selection coefficient of the disease (s), and the mutation
rate at the locus (m). Thus we have: 0vdvv,w h e r ev is defined
by v~
1{sp ðÞ m
1{p ðÞ sp
. The second criterion derived from the first
gives an upper limit of odds ratio (OR) of the pathogenic allele
for a given allele frequency in the unaffected population.
Since the association condition demands 1vOR,w eh a v e :
1vORv1z
v
M jj U 1{v{ M jj U
   for 0v M jj Uv1{v.
Since mutation rates of the putative risk loci are unknown, three
versions of the persistence criteria are shown in the Table 1. The
stronger version corresponds to the lowest mutation rate
m~1:48|10{6 per locus per generation (for mutation rates see
section 4 in Method) while the weaker version corresponds to
the highest 1:48|10{4   
and the standard version corresponds to
the average 1:48|10{5   
.
Because the estimated value of v 1:76|10{4vvv1:76|10{2   
is remarkably small, the persistence criteria is very demanding.
Among the 36 single nucleotide polymorphisms (SNPs) at
Table 1. Three versions of persistence criteria.
Stronger version Standard version Weaker version
m 1:48|10{6 1:48|10{5 1:48|10{4
n 1:76|10{4 1:76|10{3 1:76|10{2
Criterion A 0v M jj A{ M jj Uv0:000176 0v M jj A{ M jj Uv0:00176 0v M jj A{ M jj Uv0:0176
Criterion B For 0v M jj Uv0:999824 ,
ORv1z
0:000176
M jj U 0:999824{ M jj U
  
For 0v M jj Uv0:99824,
ORv1z
0:00176
M jj U 0:99824{ M jj U
  
For 0v M jj Uv0:9824,
ORv1z
0:0176
M jj U 0:9824{ M jj U
  
M jj A: Allele frequency in the affected population,
M jj U: Allele frequency in the unaffected population.
doi:10.1371/journal.pone.0007799.t001
P-Criteria
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analyses, only 9 SNPs fulfill the weaker version of the criterion A
(Table 2): the G-allele of rs1801028 (DRD2) ,t h eC - a l l e l eo f
rs1327175 (PLXNA2) ,t h eA - a l l e l eo fr s 9 9 2 2 3 6 9( RPGRIP1L),
the A-allele of rs2391191 (DAOA) ,t h eC - a l l e l eo fr s 3 5 7 5 3 5 0 5
(NRG1), the G-allele of rs4680 (COMT) ,t h eT - a l l e l eo fr s 7 3 7 8 6 5
(COMT), the T-allele of rs1011313 (DTNBP1), and the A allele
of rs3213207 (DTNBP1). None of these SNPs meet the standard
version of the criteria. Therefore, these SNPs cannot meet the
persistence criteria unless they have the highest mutation rate.
None of the recently reported common SNPs on chromosome
6p22.1 associated with SZ [31] meet the weaker version of the
criterion A (Table 3). Therefore, those common variants are
unlikely to confer susceptibility to SZ unless they have exception-
ally high mutation rates. The best imputed SNP in a recent
genome-wide association study (GWAS) [32], which reached a
genome-wide significance (the A-allele of rs3130297 on chromo-
some 6p; Pv4:69|10{7), does not meet the weaker version of
the criterion A (d.0.02; see Table 1 in the paper [32]). Therefore,
this SNP is unlikely to contribute to risk of SZ unless it has an
exceptionally high mutation rate. Similarly, none of the top 100
SNPs in a recent GWAS [32] fulfill the weaker version of the
criterion A (see Table 1 in the paper [33]).
Three of the 7 common SNPs associated with SZ in the latest
GWAS [34] clearly do not meet the weaker version of the criterion
B. The remaining 4 SNPs may fulfill the weaker version but not
the standard version (see Table 1 in the paper [34]). Therefore,
these 4 SNPs are unlikely to confer susceptibility to SZ unless they
have the highest mutation rate.
OR for a given allele frequency in the unaffected population and
the range of allele frequency in the unaffected population for a
given OR calculated with the criterion B under three levels of
mutation rate are presented in the Tables 4 and 5, respectively.
Required sample sizes for association studies for a single allele
and for GWAS are shown in the Tables 6 and 7, respectively.
Powers of association study for a single allele and of GWAS with
given sample sizes are shown in Tables 8 and 9. Surprisingly, the
power of GWAS with a sample size as large as 100,000 case-
control pairs to detect a common variant of a mutation rate not
higher than the average is almost zero (Table 9).
Discussion
The three epidemiological properties- high heritability, high
prevalence and low reproductive fitness- form a Devil’s triangle;
any combination of the two tends to exclude the third, and in this
triangle most diseases vanish except for SZ (Figure 1). Diseases
with high heritability and high prevalence such as type 2 diabetes
and adult cancers are late-onset diseases and may show almost
normal reproductive fitness. Diseases with high prevalence and
low reproductive fitness such as poor nutrition, severe injuries and
infections in childhood or early adulthood are mainly due to the
environmental factors. Diseases with low reproductive fitness and
high heritability such as most harmful Mendelian diseases in
childhood are rare. From this point of view, SZ, a disease with
those three properties, may be unique and peculiar.
This peculiar epidemiological characteristic of the disease may
put SZ in a unique position among the common diseases with
genetic bases;it might be afforded, not surprisingly, by a unique and
peculiar genetic basis. The persistence criteria, although with
notable limitations such as assuming a large effective populationsize
at equilibrium and random mating (see Method), may approxi-
mately describe the peculiarity of the genetic basis for SZ. Let us
examine the peculiarity of SZ genetics with the persistence criteria.
1. The CD/CV hypothesis is unlikely to fit SZ
First, we can see that the common disease/common variant
(CD/CV) hypothesis [35], [36] is unlikely to fit SZ. The standard
version of the criterion B implies that the OR of every risk allele
with a population frequency between 0.05 and 0.95 is less than
1.04 (Table 4). The weaker version implies that the OR of every
risk allele with a population frequency between 0.04 and 0.945 is
less than 1.50 (Table 5). Therefore, given the standard range of
mutation rate (1:48|10{6vmv1:48|10{4), the effect size and
the population frequency of a nuclear risk variant for SZ cannot
simultaneously satisfy the expectations in the CD/CV hypothesis,
in which common alleles at a handful of loci are assumed to
interact to cause a common disease.
2. Nuclear risk variant for SZ of moderate effects, if
present, should be either rare or very common
As previously mentioned, the persistence criteria argue against
the CD/CV hypothesis. However, it does not necessarily mean
that only the multiple rare variant model [37,38] fits SZ. The
standard version of the criterion B implies that the frequency of a
pathogenic variant of a moderate effect (ORw3:0) in the ncDNA,
if present, should be either very low in the affected population
( M jj Av M jj Uzvv0:0027) or very high in the normal population
( M jj Uw0:997)( Table 5). The weaker version implies that the
frequency of a nuclear susceptibility variant of a moderate effect
should be either low ( M jj Av M jj Uzvv0:027) or high
( M jj Uw0:973)( Table 5). Thus we can see that given the
standard range of mutation rate nuclear genes of moderate effects
for SZ, if present, are limited to either ‘rare variants’ or ‘very
common variants’.
‘Very common variants’ for a deleterious disease might seem at
odds; how could variants associated with a deleterious disease ever
have become so common in spite of the enormous cost the species
should pay for?
Given a much smaller effective population size in ancient times,
‘ancestral heterozygote advantage’ and genetic drift, coupled with
less pronounced reproductive disadvantage of the ancestral
patients, could provide an explanation. Although the ancestral
patients might also show a reduced reproductive fitness, the
reproductive disadvantage could have been less pronounced in
ancient environments because many patients could have children
before the onset of their illness; individuals in ancient times might
have their first children at a lower age (15–20 years=adolescence)
than individuals in modern times (25–30 years; see section 4 in
Method). Advantages of the unaffected siblings such as everyday
creativity could better work to increase their reproductive fitness in
ancient times than today. In addition, the effective population size
might be much smaller in ancient times. Thus, susceptibility genes
could have been neutral or almost neutral (selection coefficient
v
1
4Ne
; Ne = the effective population size) in ancient times. Then,
pathogenic but neutral or almost neutral genes in ancient environ-
ments could be fixed at a high frequency close to 1 by genetic drift
(because the effective population size might be much smaller and
the effects of genetic drift might be predominant in ancient times)
and can be sustained by mutation-selection balance today.
For the past two years several large-scaled association studies
including GWAS for SZ have been reported [31–34,39–45].
These reports have essentially ruled out the likelihood of a few
common variants conferring the majority of SZ heritability. On
the other hand, several groups have shown that both de novo and
inherited rare variants including copy number variants (CNV)
with high odds ratios are associated with SZ [46–51]. Although the
roles of these rare variants in the pathogenesis of SZ remain
P-Criteria
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Genes and SNPs Allele (minor/major) jM jj jA (sample size) jM jj jU (sample size) P-value OR d
1. DISC1
rs3737597 A*/G 0.07881 (N=1,142) 0.05231 (N=1,797) 0.000245 1.4 0.0265
2. SLC18A1
rs2270641 C*/A 0.31818 (N=759) 0.28022 (N=885) 0.0614 1.63 0.0380
3. GABRB2: none
4. DRD2
rs1079597 (Taql-B) A/G* 0.81325 (N=830) 0.78273 (N=803) 0.0229 1.37 0.0315
rs6277 C*/T 0.50412 (N=3,159) 0.46080 (N=4,043) 0.00000199 1.37 0.0433
rs1801028 G*/C 0.03337 (N=6,173) 0.02643 (N=7,908) 0.00323 1.22 0.0069
rs6275 T*/C 0.33862 (N=2,903) 0.31100 (N=3,336) 0.00198 1.15 0.0276
5. GWA 10q26.13
rs17101921 A*/G 0.06667 (N=7,447) 0.04318 (N=13,039) 0.00000000 1.28 0.0235
6. AKT1
rs3803300 A*/G 0.33705 (N=2,645) 0.31460 (N=2,999) 0.0257 1.05 0.0225
7. GRIN2B
rs1019385 T/G* 0.56041 (N=687) 0.48846 (N=650) 0.00050 1.33 0.0720
rs7301328 G*/C 0.44256 (N=1,088) 0.40845 (N=994) 0.0862 1.17 0.0341
8. DGCR2
rs2073776 A*/G 0.39824 (N=2,727) 0.37117 (N=3,004) 0.010 1.14 0.0271
9. PLXNA2
rs1327175 G/C* 0.92840 (N=1,711) 0.91243 (N=1,770) 0.043 1.32 0.0160
10. RPGRIP1L
rs9922369 A*/G 0.04221 (N=5,474) 0.03437 (N=10,823) 0.0014 1.3 0.0078
11. TPH1
rs1800532 A*/C 0.50726 (N=1,239) 0.45052 (N=1,708) 0.0000799 1.25 0.0567
12. DRD4
120-bp TR S/L* 0.80421 (N=1,236) 0.76397 (N=1,199) 0.00380 1.23 0.0402
rs1800955 C*/T 0.41964 (N=2,128) 0.39823 (N=2,206) 0.0653 1.13 0.0231
13. DAOA
rs3916971 T/C* 0.56220 (N=844) 0.52115 (N=922) 0.045 1.19 0.0411
rs778294 T/C* 0.78375 (N=6,444) 0.77250 (N=7,677) 0.069 1.04 0.0113
rs2391191 (M15) A*/G 0.50063 (N=8,692) 0.48820 (N=10,680) 0.029 1.01 0.0124
14. GWA 11p14.1
rs1602565 C*/T 0.14240 (N=7,170) 0.12112 (N=12,611) 0.00000001 1.16 0.0213
15. DRD1: none
16. HTR2A
rs6311 A/*G 0.44847 (N=2,678) 0.41784 (N=2,964) 0.00457 1.16 0.0306
17. RELN
rs7341475 A/G* 0.85477 (N=3,009) 0.82569 (N=7,045) 0.00000283 1.14 0.0291
18. APOE e2/3/4* 0.12061 (N=2,931) 0.10257 (N=5,065) 0.0135 1.09 0.0181
19. NRG1
rs2439272 A/G* 0.64395 (N=2,935) 0.61284 (N=2,797) 0.00101 1.18 0.0312
rs35753505 C*/T 0.42656 (N=9.082) 0.41024 (N=9,921) 0.00658 1.04 0.0163
rs473376 G*/A 0.17252 (N=3,701) 0.14611 (N=4,589) 0.0000435 1.08 0.0264
20. IL1B
rs1143634 T/C* 0.83626 (N=1,197) 0.81951 (N=1,435) 0.0564 1.06 0.0167
21. MTHFR
rs1801133 T*/C 0.34340 (N=4,055) 0.31491 (N=5,535) 0.000135 1.14 0.0341
22. COMT
rs4680 A/G* 0.58316 (N=13,282) 0.56823 (N=17,580) 0.000108 1.02 0.0149
P-Criteria
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persistence criteria. However, no reports have identified ‘very
common variants’ associated with SZ to date.
3. The largest GWAS to date lacks the power to identify a
common variant of the average mutation rate
The persistence criteria predict that common pathogenic
variants, if present, can have only tiny effects. Nevertheless,
Table 3. Common variants on chromosome 6p22.1
associated with SZ [31].
rs ID
Allele (minor/
major) jM jj jA jM jj jU P-value OR d
rs6904071 A/G* 0.834 0.814 1:78|10{8 1.14–1.25 0.020
rs926300 T/A* 0.834 0.814 1:06|10{8 1.14–1.26 0.020
rs6913660 A/C* 0.836 0.816 2:36|10{8 1.13–1.25 0.020
rs13219181 G/A* 0.837 0.817 1:29|10{8 1.14–1.26 0.020
rs13194053 C/T* 0.838 0.818 9:54|10{9 1.14–1.28 0.020
rs3800307 A/T* 0.817 0.795 4:35|10{8 1.13–1.27 0.022
rs3800316 C/A* 0.771 0.743 3:81|10{8 1.13–1.20 0.028
*alleles associated with schizophrenia, d~ M jj A{ M jj U.
doi:10.1371/journal.pone.0007799.t003
Genes and SNPs Allele (minor/major) jM jj j A (sample size) jM jj j U (sample size) P-value OR d
rs737865 C/T* 0.69100 (N=6,288) 0.67468 (N=9,131) 0.00320 0.95 0.0163
23. HP
Hp1/2 1/2* 0.62296 (N=1,346) 0.59291 (N=2,018) 0.0443 1.14 0.0300
24. DAO
rs2111902 G*/T 0.39094 (N=2,517) 0.36807 (N=2,960) 0.0455 1.07 0.0229
rs3741775 C/G* 0.57980 (N=2,514) 0.55542 (N=2,959) 0.0218 1.09 0.0244
rs3918346 A*/G 0.35145 (N=2,521) 0.32957 (N=2,966) 0.0463 1.05 0.0219
rs4623951 C/T* 0.78378 (N=1,509) 0.67883 (N=1,521) 0.0915 1.14 0.0249
25. TP53
rs1042522 C*/G 0.39880 (N=1,418) 0.36879 (N=1,410) 0.0675 1.13 0.0300
26. ZNF804A
rs1344706 G/T* 0.59933 (N=7,183) 0.58402 (N=12,663) 0.0129 1.12 0.0191
27. GWA 16p13.12
rs71992086 T*/A 0.27009 (N=7,179) 0.24558 (N=12,623) 0.00000039 1.12 0.0245
28. DTNBP1
rs1011313 T*/C 0.11722 (N=7,695) 0.10562 (N=7,276) 0.00652 1.08 0.0116
rs1018381 T/*C 0.09666 (N=4,940) 0.08727 (N=4,927) 0.0763 1.11 0.0094
rs2619538(SNPA) T*/A 0.49804 (N=5,598) 0.47671 (N=5,862) 0.00758 1 0.0213
rs3213207(P1635) G/A* 0.90835 (N=8,472) 0.89811 (N=8,391) 0.00694 1.08 0.0102
29. OPCML
rs3016384 T/C* 0.53882 (N=7,187) 0.51744 (N=12,675) 0.000264 1.08 0.0214
30. RGS4
rs2661319 (SNP16) A/G* 0.49313 (N=8,010) 0.47446 (N=9,183) 0.00249 1.08 0.0187
*alleles associated with SZ, d~ M jj A{ M jj U.
SNPs with P-value less than 0.1 are listed.
doi:10.1371/journal.pone.0007799.t002
Table 2. Cont.
Table 4. OR vs. allele frequency in the unaffected population.
Stronger version Standard version Weaker version
jM jj j U m~ ~1:48| |10{ {6 m~ ~1:48| |10{ {5 m~ ~1:48| |10{ {4
0.001 ,1.18 ,2.77 ,17.9
0.01 ,1.02 ,1.18 ,2.81
0.02 ,1.009 ,1.09 ,1.92
0.05 ,1.004 ,1.04 ,1.38
0.1 ,1.002 ,1.02 ,1.20
0.3 ,1.0009 ,1.009 ,1.09
0.5 ,1.0008 ,1.008 ,1.08
0.7 ,1.0009 ,1.009 ,1.09
0.9 ,1.002 ,1.02 ,1.24
0.95 ,1.004 ,1.04 ,1.58
0.98 ,1.009 ,1.10 ,8.49
0.99 ,1.02 ,1.22 -*
0.999 ,1.22 -* -*
*The upper limit of OR is dependent on the allele frequency in the affected
population:ORv1z
v
1{ M jj A
  
M jj A{v
   :
doi:10.1371/journal.pone.0007799.t004
P-Criteria
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more difficult than previously thought. The persistence criteria
imply that the sample size required in an association study for SZ with a
given power depends on the mutation rate at the putative risk locus as well as
the population frequency of the putative pathogenic variant. Thus we can see
that an enormous sample size is required to identify a common
pathogenic variant of a standard mutation rate (Table 6 and 7).
For example, more than the half of all the SZ patients in the world
(w3:76|107; we assume here a total human population of
6:0|109 and a prevalence of 1%) and the same number of control
subjects should be recruited to the association study to identify a
common variant (population frequency: 0.1–0.9) at a putative risk
locus of a mutation rate 1:48|10{6 with a power 0.95 (Table 6).
When the mutation rate is assumed to be average, more than one
million case-control pairs are required to identify a common
variant in a GWAS with a power 0.8 (Table 7).
Because the sample size of the largest GWAS and association
studies to date is far less than 50,000 case-control pairs (Tables 10
and 11), those studies lack the power to identify a common
pathogenic variant of the average mutation rate (Tables 8 and 9).
The power of the GWAS to identify common variants of the
highest mutation rate has merely reached to the level of ,0.1 for
the past two years (Tables 7 and 9).
4. Too strong association implies that the variants may
not confer susceptibility
Since the criterion A demands a small upper limit of the case-
control difference of the allele frequencies, too strong association
imply that the allele may not confer susceptibility to SZ.
Especially, common variants associated with SZ in an association
study with a sample size smaller than the estimations in the
Tables 6 and 7 are unlikely to contribute to risk of SZ.
Let us consider the cases of the SNPs in the Table 2. Among
the 36 SNPs that have significant P values in the meta-analyses at
Table 6. Required sample size in an association study for a
common variant.
x~ ~ jM jj j AzjM jj j U
       
2
 
v~ ~1:76| |10{ {4 v~ ~1:76| |10{ {3 v~ ~1:76| |10{ {2
0.1 or 0.9
1{b~0.95 w3:76|107 w3:76|105 w3:76|103
1{b~0.80 w2:27|107 w2:27|105 w2:27|103
1{b~0.10 w1:34|106 w1:34|104 .134
0.2 or 0.8
1{b~0.95 w6:69|107 w6:69|105 w6:69|103
1{b~0.80 w4:04|107 w4:04|105 w4:04|103
1{b~0.10 w2:38|106 w2:38|104 .238
0.3 or 0.7
1{b~0.95 w8:78|107 w8:78|105 w8:78|103
1{b~0.80 w5:31|107 w5:31|105 w5:31|103
1{b~0.10 w3:13|106 w3:13|104 .313
0.4 or 0.6
1{b~0.95 w1:00|108 w1:00|106 w1:00|104
1{b~0.80 w6:07|107 w6:07|105 w6:07|103
1{b~0.10 w3:58|106 w3:58|104 .358
0.5
1{b~0.95 w1:04|108 w1:04|106 w1:04|104
1{b~0.80 w6:32|107 w6:32|105 w6:32|103
1{b~0.10 w3:73|106 w3:73|104 .373
Samples: N cases + N controls, a~0.05, 1{b~0.95, 0.8, 0.1.
N%
z 0:05zz0:05
d
   2
x 1{x ðÞ w
3:60
v
   2
x 1{x ðÞ for 1{b~0.95.
N%
z 0:05zz0:2
d
   2
x 1{x ðÞ w
2:80
v
   2
x 1{x ðÞ for 1{b~0.80.
N%
z 0:05zz0:9
d
   2
x 1{x ðÞ w
0:68
v
   2
x 1{x ðÞ for 1{b~0.10.
doi:10.1371/journal.pone.0007799.t006
Table 5. Allele frequency in the unaffected population vs. OR.
Stronger version Standard version Weaker version
OR m~ ~1:48| |10{ {6 m~ ~1:48| |10{ {5 m~ ~1:48| |10{ {4
1.2 ,0.0009, or .0.9989 ,0.009, or .0.989 ,0.10, or .0.883
1.5 ,0.0004, or .0.9994 ,0.004, or .0.994 ,0.04, or .0.945
2.0 ,0.0002, or .0.9995 ,0.002, or .0.996 ,0.02, or .0.964
3.0 ,0.00009, or .0.9997 ,0.0009, or .0.997 ,0.009, or .0.973
5.0 ,0.00005, or .0.9997 ,0.0005, or .0.997 ,0.005, or .0.978
10.0 ,0.00002, or .0.9998 ,0.0002, or .0.998 ,0.002, or .0.980
doi:10.1371/journal.pone.0007799.t005
Table 7. Required sample size in GWAS for SZ.
x~ ~ jM jj jAzjM jj jU
       
2
 
v~ ~1:76| |10{ {4 v~ ~1:76| |10{ {3 v~ ~1:76| |10{ {2
0.1 or 0.9
1{b~0.95 w1:33|108 w1:33|106 w1:33|104
1{b~0.80 w1:04|108 w1:04|106 w1:04|104
1{b~0.10 w4:35|107 w4:35|105 w4:35|103
0.2 or 0.8
1{b~0.95 w2:38|108 w2:38|106 w2:38|104
1{b~0.80 w1:85|108 w1:85|106 w1:85|104
1{b~0.10 w7:73|107 w7:73|105 w7:73|103
0.3 or 0.7
1{b~0.95 w3:12|108 w3:12|106 w3:12|104
1{b~0.80 w2:43|108 w2:43|106 w2:43|104
1{b~0.10 w1:01|108 w1:01|106 w1:01|104
0.4 or 0.6
1{b~0.95 w3:57|108 w3:57|106 w3:57|104
1{b~0.80 w2:77|108 w2:77|106 w2:77|104
1{b~0.10 w1:16|108 w1:16|106 w1:16|104
0.5
1{b~0.95 w3:72|108 w3:72|106 w3:72|104
1{b~0.80 w2:89|108 w2:89|106 w2:89|104
1{b~0.10 w1:20|108 w1:20|106 w1:20|104
Samples: N cases + N controls, a~2:5|10{7, 1{b~0.95, 0.8, 0.1.
N%
z 0:00000025zz0:05
d
   2
x 1{x ðÞ w
6:79
v
   2
x 1{x ðÞ for 1{b~0.95.
N%
z 0:00000025zz0:2
d
   2
x 1{x ðÞ w
5:99
v
   2
x 1{x ðÞ for 1{b~0.80.
N%
z 0:00000025zz0:9
d
   2
x 1{x ðÞ w
3:87
v
   2
x 1{x ðÞ for 1{b~0.10.
doi:10.1371/journal.pone.0007799.t007
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they have the highest mutation rate. However, the remaining 27
SNPs cannot meet the criteria unless they have exceptionally high
mutation rates (w1:48|10{4). For example, the G-allele of
rs1019385 (GRIN2B), which shows P=0.0005 in the meta-
analysis, cannot meet the criteria unless the mutation rate of the
locus is higher than 6:05|10{4~
1{p ðÞ sp
1{sp
|0:072. However,
this value may be too high as compared with the upper limit of
mutation rates on autosomes and X chromosome (1:48|10{4).
Alternatively, this SNP must be a protective or resistance gene (i.e.
a gene elevating the carrier’s fitness by reducing the liability to the
disease as well as the severity of the disease).
Itshouldbenotedthathigh mutationrates(m§2:3*4:4|10{4)
have been reported on human Y chromosome [52]. Therefore,
common variants on Y chromosome or on the pseudoautosomal
regions of X chromosome where abundant mutation could be
supplied by synapsis and crossing over with Y chromosome, could
meet the persistence criteria. In this case, however, putative risk loci
would be highlypolymorphicbecause ofabundant mutation supply.
Common CNVs also could meet the criteria, if they have extremely
high mutation rates (m§1:48|10{4).
In the future, with expansion of the sample size and pooled
data, GWAS and meta-analyses may identify many more variants
associated with SZ. While some of them may fulfill the persistence
criteria, the others do not. Then, associated variants that do not
fulfill the persistence criteria should be either susceptibility genes of
exceptionally high mutation rates or resistance genes of standard
mutation rates. Thus, in the near future, we are to choose one of
the alternative cases: (1) a case in which SZ should have many
susceptibility genes with tiny effects of exceptionally high mutation
rates, or (2) a case in which SZ should have many resistance genes
of standard mutation rates on different chromosomes associated
with SZ itself. This may be the most peculiar aspect of SZ genetics
that the persistence criteria predict.
Table 8. Power of association study for a single variant.
x~ ~ jM jj j AzjM jj j U
       
2
 
v~ ~1:76| |10{ {4 v~ ~1:76| |10{ {3 v~ ~1:76| |10{ {2
0.1 or 0.9
N=10,000 ,0.03 ,0.09 ,1
N=20,000 ,0.04 ,0.13 ,1
N=50,000 ,0.04 ,0.27 ,1
0.2 or 0.8
N=10,000 ,0.03 ,0.07 ,0.999
N=20,000 ,0.03 ,0.10 ,1
N=50,000 ,0.04 ,0.17 ,1
0.3 or 0.7
N=10,000 ,0.03 ,0.07 ,0.99
N=20,000 ,0.03 ,0.08 ,0.9999
N=50,000 ,0.04 ,0.14 ,1
0.4 or 0.6
N=10,000 ,0.03 ,0.06 ,0.95
N=20,000 ,0.03 ,0.08 ,0.9999
N=50,000 ,0.04 ,0.13 ,1
0.5
N=10,000 ,0.03 ,0.05 ,0.95
N=20,000 ,0.03 ,0.08 ,0.999
N=50,000 ,0.04 ,0.13 ,1
Samples: N cases + N controls, a~0.05.
Power: 1{bvW
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
N
x 1{x ðÞ
v{z 
0:05
r   
%W
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
N
x 1{x ðÞ
r
v{1:96
  
.
doi:10.1371/journal.pone.0007799.t008
Table 9. Power of GWAS for SZ.
x~ ~ jM jj jAzjM jj jU
       
2
 
v~ ~1:76| |10{ {4 v~ ~1:76| |10{ {3 v~ ~1:76| |10{ {2
0.1 or 0.9
N=10,000 ,0.000001 ,0.00001 ,0.76
N=50,000 ,0.000001 ,0.0001 ,1
N=100,000 ,0.000001 ,0.001 ,1
0.2 or 0.8
N=10,000 ,0.000001 ,0.00001 ,0.23
N=50,000 ,0.000001 ,0.0001 ,1
N=100,000 ,0.000001 ,0.001 ,1
0.3 or 0.7
N=10,000 ,0.000001 ,0.00001 ,0.10
N=50,000 ,0.000001 ,0.0001 ,0.9999
N=100,000 ,0.000001 ,0.0001 ,1
0.4 or 0.6
N=10,000 ,0.000001 ,0.00001 ,0.07
N=50,000 ,0.000001 ,0.0001 ,0.999
N=100,000 ,0.000001 ,0.0001 ,1
0.5
N=10,000 ,0.000001 ,0.00001 ,0.06
N=50,000 ,0.000001 ,0.0001 ,0.999
N=100,000 ,0.000001 ,0.0001 ,1
Samples: N cases + N controls, a~2:5|10{7.
Power: 1{bvW
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
N
x 1{x ðÞ
v{z 
0:00000025
r   
%W
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
N
x 1{x ðÞ
r
v{5:15
  
.
doi:10.1371/journal.pone.0007799.t009
Figure 1. Devil’s triangle of high heritability, high prevalence
and low reproductive fitness. The three epidemiological properties-
high heritability, high prevalence and low fitness- form a Devil’s
triangle; any combination of the two tends to exclude the third. In this
triangle most diseases vanish except for schizophrenia.
doi:10.1371/journal.pone.0007799.g001
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Candidates Cases (Caucasian) Controls (Caucasian) Cases (Total) Controls (Total)
1. DISC1 5,762 7,449 8,006 9,697
2. SLC18A1 673 1,283 1,346 1,948
3. GABRB2 1,625 1,788 2,887 2,873
4. DRD2 8,291 11,436 10,915 14,259
5. GWA 10q26.13 5,666 11,174 7,531 13,039
6. AKT1 2,798 3,274 4,248 4,662
7. GRIN2B 737 704 1,765 1,680
8. DGCR2 1,195 1,384 5,549 5,771
9. PLXNA2 705 739 1,401 1,685
10. RPGRIP1L 5,526 10,969 5,526 10,969
11. TPH1 905 1,845 1,960 3,068
12. DRD4 4,027 5,684 7,070 8,307
13. DAOA 5,562 7,290 9,424 11,555
14. GWA 11p14.1 5,526 10,969 7,308 12,834
15. DRD1 1,303 1,917 1,502 2,213
16. HTR2A 8,226 8,809 10,907 11,284
17. RELN 3,705 8,301 4,711 9,340
18. APOE 2,624 4,646 4,693 7247
19. NRG1 7,069 9,494 12,995 15,091
20. IL1B 1,420 2,373 2,161 3,096
21. MTHFR 3,411 5,037 4,752 6,320
22. COMT 12,640 22,644 18,140 29,065
23. HP 1,300 1,966 1,863 2,492
24. DAO 1,953 2,427 3,120 3,585
25. TP53 383 443 1,418 1,410
26. ZNF804A 5,526 10,969 7,308 12,834
27. GWA 16p13.12 5,526 10,969 7,308 12,834
28. DTNBP1 8,306 9,902 10,392 11,756
29. OPCML 5,526 10,969 7,308 12,834
30. RGS4 7,756 8,983 10,466 11,711
doi:10.1371/journal.pone.0007799.t010
Table 11. Sample sizes of GWAS for SZ to date.
Study Population # of SNPs # of cases # of controls
Mah, 2006 Caucasian, USA 25,494 320 325
Lenz, 2007 Caucasian, USA 439,511 178 144
Kirov, 2008 Caucasian, Bulgaria 433,680 574 1,753
Shifman, 2008 Caucasian, Israel 510, 552 660 2,771
O’Donovan, 2008 Mixed 362,532 7,308 12,834
Sullivan, 2008 Mixed, USA 492,900 738 733
Need, 2009 European origin 555,352 1,460 12,995
Stefasson, 2009 Europe 314,868 12,945 34,591
Shi, 2009 Mixed 8,008 19,077
The International Schizophrenia
Consortium, 2009
Europe 3,322 3,587
doi:10.1371/journal.pone.0007799.t011
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We have discussed the peculiarity of SZ genetics under the
assumption that the risk loci are located in the ncDNA. Now we
shall remember that there is another possibility for the location of
the risk loci.
Another possibility is that a pathogenic gene is located in the
mitochondrial DNA (mtDNA), which shows a higher mutation
rate than the ncDNA: 8:8|10{4*1:3|10{2 per locus per
generation (4:3|10{3 on average) [53].
Because mtDNAs are transmitted only through females, the
mtDNA model could explain the persistence by a higher
reproductive fitness of the unaffected female siblings of the patients
(heterozygote advantage in this model) and/or a reduced male/
female ratio in the offspring in the predisposed matrilineal
pedigrees [54].
Interestingly, recent epidemiological studies have consistently
shown that the reproductive fitness of the unaffected female siblings
of the patients is slightly increased (1.02–1.08) [14,16,17,29]. The
epidemiological data by Haukka et al. [17] show that the slightly
increased reproductive fitness of the unaffected female siblings of
the patients (1.033), coupled with less pronounced reduced
reproductive fitness of the female patients (0.46), is sufficient for
the persistence of the disease in the mtDNA model.
Let us calculate {D, the cross-generational reduction of the
frequency of females with the pathogenic mtDNA in the general
population, using their epidemiological data (Table 12). At first
we define several notations. N1: number of the normal female
population in the first generation; N2: number of the female
offspring of the normal female population; S1: number of the
unaffected female siblings of the patients in the first generation;
S2: number of the female offspring of the unaffected female
siblings of the patients; P1: number of the female patients; P2:
number of the female offspring of the female patients; r (0,r,1):
proportion of the gene carriers in the normal female population in
the first generation. Then number of the female gene carriers
in the first generation is rN1zS1zP1 ðÞ and f1, frequency of the
female gene carriers in the first generation, is given by:
f1~
rN1zS1zP1
N1zS1zP1
~rz
S1zP1
N1zS1zP1
| 1{r ðÞ . The expected
number of the female gene carriers in the second generation is
rN1|
N2
N1
zS2zP2~rN2zS2zP2 and f2, frequency of the
female gene carriers in the second generation, is f2~
rz
S2zP2
N2zS2zP2
| 1{r ðÞ . Therefore it follows:
{D~f1{f2~
S1zP1
N1zS1zP1
{
S2zP2
N2zS2zP2
  
| 1{r ðÞ
Thus we have: {D~5:06|10{3| 1{r ðÞ v5:06|10{3
(Table 12). This implies that the gene loss can be balanced by
de novo mutation in the mtDNA which occurs at a rate of
8:8|10{4*1:3|10{2 per locus per generation (4:3|10{3 on
average) [53]. Therefore the mildly elevated reproductive fitness of
the unaffected female siblings of the patients is sufficient to sustain
the gene frequency in the mtDNA model.
In addition, in the mtDNA model, every nuclear resistance
gene may aggregate by a positive selection in the predisposed
matrilineal pedigrees that succeed to the same pathogenic
mitochondrial genome, andmaybe associated with thedisease [55].
Recently Marchbanks et al. [56] identified a heteroplasmic
mtDNA sequence variant associated with oxidative stress in SZ.
Munakata et al. [57] detected mtDNA 3243A.G mutation in the
post-mortem brain of one patient with SZ. Martorell et al. [58]
reported a heteroplasmic missense mtDNA variant in five of six
mother-offspring schizophrenic patients pairs. Although these
findings should be replicated in large-sampled studies, they may
suggest another direction to search for the solution of the big
conundrum that remains between the epidemiology and the
molecular genetics of SZ.
Methods
1. Basic assumptions
To begin, we describe our basic assumptions. These assump-
tions represent limitations of our study.
An ideal human population. Here we assume a random-
mating human population with a sufficiently large effective popu-
lation size at equilibrium, where negative selection pressures on
the susceptibility alleles for SZ are predominant and the effect of
genetic drift is negligibly small. The prevalence p (0vpv1) and
the incidence of SZ in this ideal human population are assumed to
be stable across generations through mutation-selection balance.
Mutation-selection balance in each risk locus. The
assumption that population frequency of each pathogenic allele is
preserved by mutation-selection balance may be too strong.
Therefore, we assume here that the total of the population
frequencies of the pathogenic alleles at each risk locus is preserved by
mutation-selection balance.
Multifactorial threshold model. We assume the multifac-
torial threshold model [1], in which quantitative traits such as
liability to the disease are determined by multiple genetic and non-
genetic factors including a stochastic and/or an epigenetic effect.
Under this assumption, the relative fitness as a quantitative trait in
the affected population is determined by multiple factors and
approximately follows a gamma distribution with a mean 1{s
(Figure 2). (s is the selection coefficient of SZ; the mean relative
fitness in the normal population is defined as unity.)
Table 12. Epidemiological data by Haukka et al. [17].
N S P Total (S+P)/Total
# of females 410,093 11,873 4,784 426,750 0.03903
# of female children 366,460 10,969 1,917 379,346 0.03397
{D~0:00506| 1{r ðÞ v5:06|10{3
N: Normal females; S: Unaffected female siblings of patients; P: Female patients with SZ;
r: Proportion of the gene carriers in the normal population in the first generation (0,r,1);
{D: Reduction of the frequency of females with the pathogenic mtDNA in the general population.
doi:10.1371/journal.pone.0007799.t012
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lation with an allele M never shifts to the right unless M has a
strong protective effect (i.e. an effect of elevating the affected
carrier’s fitness by reducing the severity of the disease). Since a
pathogenic allele for a deleterious disease can be assumed not to
elevate the affected carrier’s fitness, the relative fitness in the
affected subpopulation with the susceptibility allele M approxi-
mately follows a gamma distribution with a mean not greater than
1{s (i.e. 1{sM; sƒsMv1).
No special assumptions else are required on the allelic structure
in each locus, penetrance of each susceptibility gene, and possible
interactions among the loci. It should be noted that the nuclear
single major gene locus model is included as a special case in the
assumptions.
2. Notation
Risk loci, two equivalent classes of alleles, and allele
frequencies. Suppose that there are n risk loci L1,L2,:::,LN for
SZ and that each locus has two equivalent classes of alleles:
pathogenic and non-pathogenic. Let ~ P Pi~ Pik fg and ~ N Ni~ Nij
  
denote these classes at the risk locus Li. When subscripts i and k
are omissible, we simply use the symbols L, M, and ~ M M to denote a
risk locus, a pathogenic allele at the risk locus, and the pathogenic
class of alleles including M at the locus, respectively.
Let M jj A, M jj U, and M jj G denote the frequency of an allele M
in the affected, the unaffected and the general population,
respectively. We define ~ P Pi
       
A, ~ P Pi
       
U, and ~ P Pi
       
G by the equations:
~ P Pi
       
A~
P
k Pik jj A, ~ P Pi
       
U~
P
k Pik jj U, and ~ P Pi
       
G~
P
k Pik jj G.
From definition we have the following equations: for a given
pathogenic allele M, M jj G~pM jj Az 1{p ðÞ M jj U,o r
M jj A{ M jj G~ 1{p ðÞ M jj A{ M jj U
  
: ð1Þ
Cross-generational reductions of the population fre-
quencies of the pathogenic alleles due to the decreased
reproductive fitness of the affected population. {D ~ M M
       
G~
cross-generational reduction of ~ M M
       
G by natural selection
{D M jj G~ cross-generational reduction of M jj G by natural
selection
It may be trivial that {D ~ P Pi
       
G~
P
k {D Pik jj G§{D Pik jj G.
Therefore we have : {D ~ M M
       
G§{D M jj G: ð2Þ
Mutation and mutation rates. Mutation occurs in the
following directions at each risk locus Li : ~ N Ni?~ P Pi, ~ N Ni?~ N Ni,
~ P Pi?~ P Pi,o r~ P Pi?~ N Ni. Therefore, we use the following notations:
m i ðÞ~ mutation rate at the risk locus Li, m i ðÞ
N?P~ rate of
mutation which occurs in the direction ~ N Ni?~ P Pi at the locus Li,
m i ðÞ
N?N~ rate of mutation which occurs in the direction ~ N Ni?~ N Ni
at the locus Li, m i ðÞ
P?P~ rate of mutation which occurs in the
direction ~ P Pi?~ P Pi at the locus Li, m i ðÞ
P?N~ rate of mutation which
occurs in the direction ~ P Pi?~ N Ni at the locus Li, m i ðÞ
p~ rate of
mutation which produces pathogenic alleles at the locus Li, m~
mutation rate at the risk locus L, mM~ rate of mutation which
produces the pathogenic allele M at the locus L, m ~ M M~ rate of
mutation which produces the pathogenic alleles at the locus L.
From definition we have: m i ðÞ~m i ðÞ
N?Pzm i ðÞ
N?Nzm i ðÞ
P?Pz
m i ðÞ
P?N, m i ðÞ
P~m i ðÞ
N?Pzm(i)
P?P{m(i)
P?Nvm(i), and m i ðÞ
Pikƒ
m i ðÞ
Pvm i ðÞ.
Therefore we have : mMvm ~ M Mvm: ð3Þ
Mutation2selection balance ineach risk locus implies :
{D ~ M M
       
G~m ~ M M: ð4Þ
3. Deduction of the persistence criteria
Now we proceed to deduce the persistence criteria. From the
assumptions it follows that M jj 0
G, the population frequency of
the pathogenic allele M in the next generation, is given by:
M jj 0
G~
pM jj A: 1{sM ðÞ z 1{p ðÞ : M jj U:1
p: 1{s ðÞ z 1{p ðÞ :1
~
M jj G{sMpM jj A
1{sp
ƒ
M jj G{sp M jj A
1{sp
. Therefore the reduction of the population
frequency of the allele M per generation is: {D M jj G~
M jj G{ M jj 0
G§ M jj G{
M jj G{sp M jj A
1{sp
~
sp M jj A{ M jj G
  
1{sp
~
sp 1{p ðÞ M jj A{ M jj U
  
1{sp
From (2), (3) and (4) it follows:
sp 1{p ðÞ M jj A{ M jj U
  
1{sp
ƒ { D M jj Gƒ{D ~ M M
       
G~m ~ M Mvm.
Thus we have the first criterion for a susceptibility gene
(criterion A):
Criterion A. M jj A{ M jj Uvv, where n is defined by
v~
1{sp ðÞ m
1{p ðÞ sp
.
Criterion A implies: M jj Av M jj Uzv. Since the odds ratio (OR)
of the allele M, defined by OR~
M jj A 1{ M jj U
  
1{ M jj A
  
M jj U
, is monotonically
increasing for 0v M jj Av1, it may be trivial: if 0v M jj Uv1{v,
OR~
M jj Uzv
  
1{ M jj U
    
1{ M jj Uzv
     
M jj U
~1z
v
M jj U 1{v{ M jj U
  .
Thus we have the second criterion for a susceptibility gene
(criterion B):
Criterion B. If 0v M jj Uv1{v, ORv1z
v
M jj U 1{v{ M jj U
  .
Since criterion A also implies M jj A{vv M jj U and OR is
monotonically decreasing for 0v M jj Uv1, we can easily see: if
1{vv M jj Uv1,OR~
M jj A 1{ M jj A{v
       
1{ M jj Azv
  
M jj A{v
   ~1z
v
1{ M jj A
  
M jj A{v
   :
Figure 2. Distribution of the relative fitness in the affected
population. In the multifactorial threshold model, the relative fitness
as a quantitative trait in the affected population is assumed to
approximately follow a gamma distribution with the mean 1{s. The
distribution curve in the affected subpopulation with an allele M shifts
to the right only if M has a strong protective effect. Thus it can be
assumed that the relative fitness in the affected subpopulation with a
pathogenic allele M approximately follows a gamma distribution with a
mean not greater than 1{s (i.e. 1{sM; sƒsMv1).
doi:10.1371/journal.pone.0007799.g002
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4. Numerical estimates of parameters in SZ genetics
It is now known that mutation rates on autosomes and X
chromosomes almost always fall within the range of 10
26 to 10
24
per locus per generation (usually v10{5; one generation =20
years) [59,60]. Advancing parental ages could elevate the mutation
rate [61]. Although it seems to increase as an exponential of the
parental age in some loci, it can be approximated by a linear
function of the parental age at least under 30 years for maternal
age and under 40 years for paternal age [61]. On the other hand,
large sampled cohort studies in Israel, Sweden and Denmark show
that the mean age of parents in the general population is ,28
years for mothers and ,31 years for fathers; the mean age of both
parents is ,29.6 years [62,63]. Therefore we can assume:
1:48|10{6~
29:6
20
|10{6vmv
29:6
20
|104~1:48|10{4:
We can know the values of the parameters p and s from the
epidemiological studies. Among the many epidemiological studies
on the fertility of SZ, the cohort study by Haukka et al. [17] is the
largest in sample size (N=870,093) and the lowest in sampling
bias. They comprised all births in Finland during 1950–1959 and
followed up through the National Hospital Discharge Register for
Hospitalizations between 1969 and 1992. Estimated values for p
and s are p~1:29|10{2 and s~6:54|10{1. Thus, we have:
1:76|10{4vvv1:76|10{2.
The estimated value of v for SZ may be remarkably small. This
sums up the epidemiological characteristics of SZ which
discriminate it from other common diseases with genetic bases
such as type 2 diabetes and most adult cancers. For those diseases
v would be much greater due to much smaller s values because
most patients with those diseases manifest after the reproductive
age (.40 years). On the other hand, SZ manifests typically in
adolescence or early adulthood, and specific symptoms of the
disease such as an autistic way of life and bizarre behaviors reduce
the reproductive fitness of the patients as has been shown by most
epidemiological studies.
It should be noted that contribution of advancing parental ages
to pathogenic mutations seems not very large in SZ. That is
because large sampled cohort studies have shown that the
proportions of older parents both in the affected and the normal
populations are equally small (,7.7% and ,5.5% for fathers older
than 45 years in the affected and the normal populations
respectively; and ,9.9% and ,8.7% for mothers older than 35
years) [64,65]. In addition, the differences in the mean ages of
parents between the affected and the normal individuals are not
very large (,1.7 years for fathers and ,0.8 year for mothers)
[62,63] even if they are statistically significant.
Some researchers have proposed the hypothesis that SZ is
associated with de novo mutations arising in paternal germ cells
[62–66]. It is based on the observation (‘paternal age effect’) that
the risk of SZ in the offspring seems to increase as paternal age
advances from 20 years to over 50 years. However, the risk of SZ
was also increased in the offspring of younger men (,21 years)
[62,63,66] as well as in the offspring of younger women (,20
years) [63]. Therefore, major roles of paternally derived mutations
in SZ seem to remain unsubstantiated. Indeed, no available data
can exclude the possibility that the ‘paternal age effect’ on the risk
of SZ may be due to putative maternal factors; while women in
many countries today may be usually supposed to bear children
after the age of 20 years or to marry much older men only when
the men have socio-economic benefits, predisposed women might
bear children before the age of 20 years or choose too young or too
old men as fathers of their children even if the men have no socio-
economic benefits.
5. Validity-testing of the candidate genes in the literature
with the criteria
We tested whether the 111 SNPs of the top 30 genes listed in
the meta-analyses at SZGene (http://www.schizophreniaforum.
org/res/szgene/default.asp) [30] meet the persistence criteria.
S i n c eS Z G e n ei sb e i n gp e r i o d i c a l l yu p - d a t e d ,w eu s e dt h e
version on 10
th August, 2009. Based on the genotype distribu-
tions in meta-analyses, allele frequencies and the case-control
differences were calculated. We also tested the top 100 SNPs
listed in a recent GWAS by Need et al. [33] as well as the
c o m m o nv a r i a n t sr e p o r t e di nt h el a t e s tG W A S sb yS h ie ta l .
[31], by Stefasson et al. [34], and by The International
Schizophrenia Consortium [32].
6. Power and sample size estimation in case-control
association studies for SZ
Let W : {?,? ðÞ ? 0,1 ðÞ be the cumulative distribution
function of the standard normal curve and let W{1 :
0,1 ðÞ ? {?,? ðÞ be its inverse function. The upper b point of
the standard normal curve is given by zb~W{1 1{b ðÞ and the
two sided a point by z a~za=2. In a case-control association study
of a single variant M with sample size 2N (N cases + N controls) at a
significance level a, the power 1{b is given by 1{b%
W
ﬃﬃﬃﬃﬃﬃﬃ
2N
p
d{z a
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2x 1{x ðÞ
p
c
 !
,o rN%
1
2
z a
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2x 1{x ðÞ
p
zzbc
d
 ! 2
,
where x, c2, and d are defined by the equations: x~
1
2
M jj Az M jj U
  
,c2~ M jj A 1{ M jj A
  
z M jj U 1{ M jj U
  
, and
d~ M jj A{ M jj U. [67,68]
Since the criterion A (0vdvv) warrants 0v
1
2
d2vv2x 1{x ðÞ
for 0.1,x,0.9, we have: c2~2x{
1
2
2x ðÞ
2zd2
no
%2x 1{x ðÞ ,o r
c%
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2x 1{x ðÞ
p
. Thus we have: 1{b%W
ﬃﬃﬃﬃﬃﬃﬃ
2N
p
d{z 
a
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2x(1{x)
p
c
 !
%
W
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
N
x(1 {x)
s
d{z 
a
 !
vW
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
N
x(1 {x)
s
v{z 
a
 !
, and N%
z azzb
d
   2
x(1{x)w
z azzb
v
   2
x 1{x ðÞ for 0.1,x,0.9.
We calculated the power of the association study for sample
sizes N=10000, 20000, 50000, 100000 under three levels of
mutation rates. For the calculation of N required in the association
study for a single allele, we assume: a~0.05 and 1{b~0.95, 0.8,
0.1. For the calculation of N required in GWAS, we assume:
a~2:5|10{7 and 1{b~0.95, 0.8, 0.1.
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